Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
32.37
+0.33 (1.03%)
May 9, 2025, 10:44 AM - Market open
Legend Biotech Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Legend Biotech stock have an average target of 79.42, with a low estimate of 60 and a high estimate of 90. The average target predicts an increase of 145.35% from the current stock price of 32.37.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Legend Biotech stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 5 |
| Buy | 7 | 7 | 7 | 7 | 6 | 7 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $84 | Buy | Reiterates | $84 | +159.50% | Apr 22, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +131.70% | Apr 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +131.70% | Apr 8, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $82 → $80 | Buy | Maintains | $82 → $80 | +147.14% | Mar 17, 2025 |
| Guggenheim | Guggenheim | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 12, 2025 |
Financial Forecast
Revenue This Year
1.04B
from 627.24M
Increased by 65.96%
Revenue Next Year
1.59B
from 1.04B
Increased by 52.55%
EPS This Year
-0.72
from -0.97
EPS Next Year
0.33
from -0.72
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.2B | 2.0B | 2.9B | ||
| Avg | 1.0B | 1.6B | 2.1B | ||
| Low | 901.6M | 1.2B | 1.7B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 87.0% | 89.6% | 82.1% | ||
| Avg | 66.0% | 52.5% | 34.9% | ||
| Low | 43.7% | 15.2% | 9.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.29 | 0.83 | 1.07 | ||
| Avg | -0.72 | 0.33 | 0.79 | ||
| Low | -1.32 | -0.02 | 0.37 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 225.3% | ||
| Avg | - | - | 141.3% | ||
| Low | - | - | 13.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.